UNAIR NEWS – Tuberculosis (TB) is a persistent disease. It is difficult to deal with the illness which attacks and destroys lungs. It made Indonesia as one of many countries with high prevalence of TB. TB control program has been implemented for 20 years but until now TB still becomes third infectious disease with most suffering and death in Indonesia.
”We try to deal with it for decades. A lot of people recover and healed. But it keeps recurring and causing new problems. It inspired UNAIR to hold this seminar which invited TB experts from many countries on August 8-9, 2016 to find the solutions,” said Dr. Soedarsono, dr., Sp.P(K), Head of the committee of“International Seminar on Global Strategy to Combat Emerging Infectious Diseases in Borderless Era” (GSEID 2016).
In a press conference in FK UNAIR last Friday, July 29, Dr. Soedarsono was with other experts on microbiology and TB experts such Prof. Dr. Kuntaman, dr., MS., Sp.MK(K)., Prof. Dr. Ni Made Mertaniasih, dr., MS., Sp.MK(K) Vice Dean III FK UNAIR, and Prof. Maria Inge Lusida, dr., M.Kes., Ph.D., Sp.MK(K) Head of Institute of Tropical Diseases (ITD) UNAIR. The seminar was held in collaboration of FK and ITD UNAIR, in FK UNAIR Hall. It will invite a keynote speaker dr. H. Muhamad Subuh, MPPM., General Director of P2P Indonesian Ministry of Health.
International experts to be presented are Prof. Toshiro Shirakawa MD., Ph.D (Kobe University), Prof. Keigo Shibayama MD, Ph.D (National Institute of Infectious Disease, Japan), Prof. Katsushi Tokunaga, PhD (Tokyo University), Prof. Dr. Mark A. Graber, MD, MSHCE, FACEP (Iowa University USA), Prof. Dr. Eric C.M van Gorp (Erasmus Medical Center, Rotterdam), and Dr. Carmelia Basri, M.Epid (Senior Public Health Consultant).
Recent cases of TB appearance such as comorbidity HIV-AIDS, diabetes, Mycobacterium tuberculosis resistance or drug resistant germ or known as multi-drug resistance (TB MDR). Those cases were believed to occur because of non-stop TB treatment for six months, boredom, medication changing, half dosage consumption, so the disease does not heal and the causing bacteria (Mycobacterium tuberculosis complex) become resistant to medication.
“Those kinds of cases will be discussed in the seminar, including its treatment by collaborating researches’ results of international experts,” said Dr. Soedarsono.
At global level, Indonesia is currently at eighth out of 27 countries with the biggest TB-MDR in the world, with patients of TB-MDR reaching 6,900 cases. TB-MDR treatment program has been implemented in Indonesian hospitals since 2009.
“There are many challenges to deal with, slow TB-MDR treatment program implementation in hospital, fast diagnosis problem, more side effects, less commitment of many parties have made TB-MDR transmitted faster. So there should be an intervention by looking for the root of all problems so the TB-MDR treatment program can succeed in the future,” said Soedarsono, a pulmonologist of RSUD Dr.Soetomo/FK UNAIR.
Added by Prof. Kuntaman, resistant bacteria which are getting great global attention are MRSA (Methicillin Resistant Staphycoccus aureus) which are resistant to all penicillin drugs. Its prevalence in 2002 was less than 1% and now it becomes 8%.
Second group is ESBL (Extended Spectrum Beta Lactamase) bacteria producer which are resistant to new generation antibiotics such as penicillin and its kinds except some which are still sensitive.
“In 2006, it was 24%, but in 2013 it reached 38-66%. So at this moment, it is predicted even higher,” said Prof. Kuntaman.
The third group is Carbapenem Resistance Enterobacteriaceae (CRE) which is the latest threat. The bacteria have been resistant to all antibiotics in the world.
“The bacteria have been detected in Indonesia, especially Jakarta and Surabaya. Indonesia is a vast country, so information on these resistant bacteria might not well circulated. It is our responsibility to inform about it,” added the professor on Clinical Microbiology of FK UNAIR. (*)
Author: Bambang Bes